Clinical features and mutation characteristics of the patients with leukemia secondary to MPD
| Age/sex . | Diagnosis . | Therapy . | Latent period (mo) . | Chromosome . | AML1 mutation . | Case no. . | ||
|---|---|---|---|---|---|---|---|---|
| Chronic state . | Leukemic state . | Chronic state . | Leukemic state . | |||||
| 61/F | MF→AML (M1) | Radiation 40 Gy, BUS, HC, INFα | 123 | 46, XX | 46, XX | WT | 343_364dup, Ala122fsTer123 | 11 |
| 57/F | ET→AML (M4) | BUS, HC | 182 | 46, XX | 45, XX, −18 | WT | 517C>T, Pro173Ser | 12 |
| 64/M | PV→AML (M1) | BUS | 60 | ND | 46, XY | ND | 511G>A, Asp171Asn | 13 |
| 72/F | ET→AML (M1) | HC | 108 | 46, XX | 46, XX | WT | WT | — |
| 58/M | PV→AML (M1) | HC, 6MP, INFα | 132 | 46, XY | 46, XY, 20q- | WT | WT | — |
| 56/M | ET→AML (M7) | HC | 24 | 46, XY | 46, XY | WT | WT | — |
| 29/F | PNH→AML (M4) | PSL | 94 | 46, XX | 45, XX, −7 | WT | WT | — |
| Age/sex . | Diagnosis . | Therapy . | Latent period (mo) . | Chromosome . | AML1 mutation . | Case no. . | ||
|---|---|---|---|---|---|---|---|---|
| Chronic state . | Leukemic state . | Chronic state . | Leukemic state . | |||||
| 61/F | MF→AML (M1) | Radiation 40 Gy, BUS, HC, INFα | 123 | 46, XX | 46, XX | WT | 343_364dup, Ala122fsTer123 | 11 |
| 57/F | ET→AML (M4) | BUS, HC | 182 | 46, XX | 45, XX, −18 | WT | 517C>T, Pro173Ser | 12 |
| 64/M | PV→AML (M1) | BUS | 60 | ND | 46, XY | ND | 511G>A, Asp171Asn | 13 |
| 72/F | ET→AML (M1) | HC | 108 | 46, XX | 46, XX | WT | WT | — |
| 58/M | PV→AML (M1) | HC, 6MP, INFα | 132 | 46, XY | 46, XY, 20q- | WT | WT | — |
| 56/M | ET→AML (M7) | HC | 24 | 46, XY | 46, XY | WT | WT | — |
| 29/F | PNH→AML (M4) | PSL | 94 | 46, XX | 45, XX, −7 | WT | WT | — |
MF indicates myelofibrosis; ET, essential thrombocythemia; PV, polycythemia vera; PNH, paroxysmal nocturnal hematuria; BUS, busulfan; HC, hydroxycarbamide; 6MP, mercaptopurine; PSL, prednisolone; ND, not done; WT, wild-type; and —, case number not assigned.